Sirolimus (Rapamycin)

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Also Known As:

Networked: 10003 relevant articles (998 outcomes, 1727 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Serruys, Patrick W: 84 articles (03/2024 - 06/2002)
2.	Park, Seung-Jung: 43 articles (03/2024 - 02/2005)
3.	Leon, Martin B: 39 articles (03/2015 - 10/2003)
4.	Kastrati, Adnan: 38 articles (10/2021 - 08/2004)
5.	Blagosklonny, Mikhail V: 37 articles (01/2024 - 09/2006)
6.	Windecker, Stephan: 37 articles (11/2023 - 01/2003)
7.	Valgimigli, Marco: 36 articles (01/2023 - 05/2004)
8.	Liu, Yang: 35 articles (08/2022 - 12/2011)
9.	Park, Duk-Woo: 32 articles (03/2024 - 09/2005)
10.	Kwiatkowski, David J: 32 articles (03/2024 - 09/2003)

Related Diseases

1.	Neoplasms (Cancer) 11/12/2021 - "In addition, we further showed that chronic rapamycin treatment did not have any apparent tumor-suppressing effects on DEN&HFD treated control mice, whereas it dramatically reduced the tumor burden in mice with hepatic Depdc5 ablation. " 04/01/2009 - "Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human breast epithelial cells, relative to MCF10CA1a tumor cells. " 01/22/2008 - "Tumor cell proliferation (measured by Ki-67 staining) was dramatically reduced in seven of 14 patients after 1 wk of rapamycin treatment and was associated with the magnitude of mTOR inhibition (p = 0.0047, Fisher exact test) but not the intratumoral rapamycin concentration. " 06/01/1983 - "A new drug (rapamycin) being investigated by the NCI was found to be very effective against the U-251 tumor. " 09/01/2023 - "Additionally, CTR1 gene silencing successfully improved the anti-cancer effect of mTOR inhibitor rapamycin. "
2.	Tuberous Sclerosis (Bourneville's Disease) 07/01/2015 - "Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future." 03/01/2005 - "Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models." 01/01/2021 - "Study on the Treatment of Tuberous Sclerosis with Rapamycin Nanomicelles Based on Abdominal Ultrasound." 02/01/2015 - "This study explores the role of tuberous sclerosis complex 1 (TSC1)-mechanistic target of rapamycin (mTOR) signaling in the conversion of brown to white adipose tissue (WAT). " 09/15/2013 - "  The goal of this study was to determine whether the mechanical activation of mechanistic target of rapamycin (mTOR) signalling is associated with changes in phosphorylation of tuberous sclerosis complex-2 (TSC2) and targeting of mTOR and TSC2 to the lysosome. "
3.	Inflammation (Inflammations) 07/01/2020 - "The rapamycin-treated group exhibited significantly decreased severe inflammation and improved muscle strength compared with the MP-treated group. " 11/01/2016 - "Intravitreal sirolimus 440 μg demonstrated a significant improvement in ocular inflammation with preservation of BCVA in subjects with active NIU of the posterior segment." 01/01/2015 - "Inflammation and oxidative stress were significantly decreased and the bladder histology and micturition function were significantly improved with rapamycin (RAPA, autophagy agonist) pre-treatment. " 12/01/2006 - "Both rapamycin and CsA treatments significantly improved the histologic inflammation score. " 01/01/2022 - "These parameters were improved in rapamycin-pretreated elderly mice, which exhibited a better parasitological control, reduced heart inflammation and microstructural damage. "
4.	Angiofibroma 03/01/2023 - "Topical rapamycin can be considered an effective and safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has yet to be established. " 01/01/2018 - "Clinically meaningful and statistically significant improvement in facial angiofibromas was observed for both 1% and 0.1% rapamycin relative to the vehicle-only control group, and for 1% vs 0.1% rapamycin, with most of the improvement realized within the first month. " 01/01/2015 - "Topical rapamycin can be considered a safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has not been established. " 03/31/2022 - "The NMA found when compared with placebo, facial angiofibromas significantly improved following the application of various concentrations of topical sirolimus (risk ratio being 3.87, 2.70, 4.43, and 3.34 for 0.05%, 0.1%, 0.2%, and 1%, respectively). " 07/01/2014 - "Sirolimus has been shown to be beneficial in treating facial angiofibromas. "
5.	Coronary Artery Disease (Coronary Atherosclerosis) 01/01/2019 - "Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials." 05/01/2003 - "Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty." 01/01/2023 - "Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial." 01/01/2023 - "Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient-level pooled analysis of NeoVas trials." 01/01/2022 - "A First-in-Human Study of the Bioheart Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: Two-Year Clinical and Imaging Outcomes."

Related Drugs and Biologics

1.	TOR Serine-Threonine Kinases
2.	Everolimus
3.	Sirolimus (Rapamycin)
4.	MTOR Inhibitors
5.	Mechanistic Target of Rapamycin Complex 1
6.	trans-sodium crocetinate (crocetin)
7.	Polymers
8.	Cyclosporine (Ciclosporin)
9.	Paclitaxel (Taxol)
10.	Tacrolimus (Prograf)

Related Therapies and Procedures

1.	Stents
2.	Therapeutics
3.	Transplantation
4.	Liver Transplantation
5.	Drug-Eluting Stents